Epigenetics 2009

 
 
 

The 4th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy took place January 16-18, 2009, in Coral Gables, Florida.

 

Focus on epigenetics and stem cells

Jen Smith Read Article
Published: 02/11/09

Craig T. Jordan, PhD
Craig T. Jordan, PhD

At the 4th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy, several speakers presented novel findings in a session focused on epigenetics and stem cells. Craig T. Jordan, PhD, of University of Rochester Medical Center, began the session by discussing promising study results that indicate we may be able to directly target leukemia stem cells (LSCs) while sparing normal hematopoetic stem cells (HSCs). He presented research demonstrating that the plant-derived compound parthenolide, a known NF-kB inhibitor, can specifically ablate LSCs. [Read Article]

Current concepts of epigenetic regulation in cancer

Jonathan Licht, MD Read Article
Published: 02/04/09

Jonathan Licht, MD
Jonathan Licht, MD

Several investigators led off the 4th Biennial Workshop on Clinical Translation of Epigenetics in Cancer Therapy with a basic science overview of epigenetic regulation. Jonathan Licht, MD, of Northwestern University in Chicago, has provided HematologyTimes with a summary of this ongoing research, which includes the epigenetic nature of stem cells, the characterization of chromatin modulating pathways, and the activities of histone methyl transferases, among other topics. [Read Article]

Professor offers insights on epigenetics workshop

Samuel Waxman, MD Read Article
Published: 02/02/09

Samuel Waxman, MD
Samuel Waxman, MD

More than 100 physicians and scientists involved in epigenetic research convened in Coral Gables, Florida, for the 4th Biennial Workshop on Clinical Translation of Epigenetics in Cancer Therapy. Samuel Waxman, MD, Distinguished Professor of Medicine at Mount Sinai School of Medicine, has provided HematologyTimes with an inside look at the meeting, from current concepts of epigenetic regulation to epigenomic profiling, predictors, and biomarkers. [Read Article]

Azacitidine plays key role in epigenetic therapy

Jen Smith Read Article
Published: 01/21/09

Bone marrow aspirate showing MDS
Bone marrow aspirate
showing MDS

Discoveries presented at the 4th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy may change the way clinicians use azacitidine. New research discussed at the workshop pinpoints the optimal dose and administration route for azacitidine, reveals a new method to distinguish responding patients from nonresponders, suggests the drug effectively treats multiple myeloma, and demonstrates that azacitidine is synergistic with other agents. [Read Article]

Findings could improve targeted leukemia therapy

Jen Smith Read Article
Published: 01/20/09

New research further clarifies the interaction between the MLL gene and menin, a finding that may pave the way for the development of more effective targeted leukemia therapy. Michael T. Thirman, MD, of the University of Chicago, and colleagues conducted a study to better define MLL-menin interaction and presented their results at the 4th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy, which took place January 16-18 in Coral Gables, Florida. [Read Article]

Mechanisms of HDAC inhibitors revealed

Jen Smith Read Article
Published: 01/20/09

 Wilson H. Miller, Jr, MD, PhD
Wilson H. Miller, Jr, MD, PhD

A new study has revealed the mechanisms by which two HDAC inhibitors trigger apoptosis in hematologic malignancies. Though previous studies have shown that panobinostat and vorinostat both effectively inhibit HDACs, scientists could not elucidate the agents’ precise mechanisms of action. Now, in a presentation at the 4th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy, a group of researchers say they have. [Read Article]

HDAC inhibitors and apoptosis in AML

Jen Smith Read Article
Published: 01/19/09

Michael Andreeff, MD, PhD
Michael Andreeff, MD, PhD

Researchers say they have uncovered a novel mechanism of HDAC inhibitor-induced apoptosis in AML. Michael Andreeff, MD, PhD, of M.D. Anderson Cancer Center, and colleagues have found that an HDAC inhibitor mediates silenced gene expression of the orphan nuclear receptors Nur77 and Nor1, and this phenomenon plays a major role in the pathogenesis of AML. Dr Andreeff presented these results at the 4th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy. [Read Article]

Novel pathway of transformation from MDS to AML

Jen Smith Read Article
Published: 01/19/09

 Steve Gore, MD
Steve Gore, MD

Progressive inactivation of alpha-catenin may represent a novel pathway of transformation from MDS to AML, according to a speaker at the 4th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy. Steve Gore, MD, of Sidney Kimmel Comprehensive Cancer Center, and colleagues found that methylation of the alpha-catenin promoter gene is common in AML patients (regardless of 5q deletion status), but rare in patients with MDS. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}